Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 References  














Iopamidol






Deutsch
Italiano
Nederlands
Oʻzbekcha / ўзбекча
Српски / srpski
Srpskohrvatski / српскохрватски
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Iopamidol
Clinical data
Trade namesIsovue, Iopamiro, Gastromiro, others[1]
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
Intravascular, intravenous, intrathecal
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[3]
  • US: WARNING[2]Rx-only[4][5]
  • Identifiers
    • 1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide

    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.056.430 Edit this at Wikidata
    Chemical and physical data
    FormulaC17H22I3N3O8
    Molar mass777.089 g·mol−1
    3D model (JSmol)
    • C[C@@H](C(=O)Nc1c(c(c(c(c1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O

    • InChI=1S/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1

    • Key:XQZXYNRDCRIARQ-LURJTMIESA-N

     ☒NcheckY (what is this?)  (verify)

    Iopamidol (INN), sold under the brand name Isovue among others, is a nonionic, low-osmolar iodinated contrast agent, developed by Bracco Diagnostics.

    It is available in various concentrations, from 200 to 370 mgI/mL.[5]

    Medical uses[edit]

    Iopamidol is indicated for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.[5]

    It is also indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography. Isovue-M 200 (lopamidol Injection) is indicated for thoraco-lumbar myelography in children over the age of two years.[4]

    As with other iodinated contrast agents there are concerns regarding safety, particularly relating to effects on renal function and allergic type reaction. Early generations of intravenous (IV) contrast carried considerable nephrotoxicity, necessitating continual assessment of renal function. IV and PO (per os, by mouth) fluids are encouraged post operation to facilitate excretion of contrast. Shellfish allergies have previously thought to have crossover with iodine allergies with caution being advised with regards to the use of iodinated contrast in patients with shellfish, however shellfish have been demonstrated to be due to proteins produced by the organisms, not due to iodine.[citation needed]

    References[edit]

    1. ^ "Iopamidol". Drugs.com. 10 August 2020. Retrieved 14 August 2020.
  • ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  • ^ "Gastromiro - Summary of Product Characteristics (SmPC)". (emc). Retrieved 14 August 2020.
  • ^ a b "Isovue-M- iopamidol injection, solution". DailyMed. 24 October 2019. Retrieved 14 August 2020.
  • ^ a b c "Isovue 300- iopamidol injection, solution Isovue 370- iopamidol injection, solution Isovue 200- iopamidol injection, solution Isovue 250- iopamidol injection, solution". DailyMed. 1 December 2019. Retrieved 14 August 2020.
  • ^ "Iopamidol Use During Pregnancy". Drugs.com. 31 March 2020. Retrieved 14 August 2020.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Iopamidol&oldid=1227815646"

    Categories: 
    Radiocontrast agents
    Iodobenzene derivatives
    Benzamides
    Acetanilides
    Pharmacology stubs
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Drugs with non-standard legal status
    Articles with changed CASNo identifier
    Articles with changed DrugBank identifier
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
    Wikipedia articles needing clarification from February 2018
    All Wikipedia articles needing clarification
    All articles with unsourced statements
    Articles with unsourced statements from July 2020
    All stub articles
     



    This page was last edited on 7 June 2024, at 23:29 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki